Small molecules, a growing class of targeted therapies, have flourished over the last decade. With increased knowledge on molecular cell signaling, targeted therapy has been refined to targeting molecular targets upstream from the nucleus that are key players in the communication system that regulates cancer cell growth. This article reviews the mechanisms of small molecules with a particular emphasis on tyrosine kinase inhibitors, as well as the literature that supports the current clinical use in the treatment of a variety of solid and hematological malignancies.
Jonge MJ, Verweij J.Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all? Euro J Cancer. 2006;42:1351-1356.
2.
Krause DS, Van Etten RATyrosine kinases as targets for cancer therapy. N Engl J Med . 2005;353:172-187.
3.
Arora A., Scholar EMRole of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315:971-979.
4.
Harari PM, Allen GW, Bonner JABiology of interactions: antiepidermal growthfactor receptor agents . J Clin Oncol. 2007;25:4057-4065.
5.
Citri A., Yosef Y.EGF-ERBB signaling: towards the systems level. Nat Rev: Mol Cell Biol. 2006;7:505-516.
6.
Charpin C., Garcia S., Bouvier C., et al. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival . Br J Cancer. 1997;75:1667-1673.
7.
Press MJ, Bernstein L., Thomas PA, et al. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-2904.
8.
Camilleri-Broet S., Hardy-Bessard AC, Tourneau AL, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol. 2004 ;15:104-112.
9.
Algire GH, Chalkley HWVascular reactions of normal and malignant tumors in vivo. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst. 1945;6:73-85.
10.
Folkman J., Cole P., Zimmerman S.Tumor behavior in isolated perfused organs: in vitro growth and metastasis of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg. 1966;164:491-502.
11.
Gimbrone MA Jr, Cotran RS, Leapman SB, Folkman J.Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst. 1974;52:413-427.
12.
Liotta L., Kleinerman J., Saldel G.Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 1974;34:997-1004.
13.
Srivastava A., Laidler P., Davies RP, Horgan K., Hughes LEThe prognostic significance of tumor vascularity in intermediate-thickness skin melanoma . Am J Pathol. 1988;133:419-423.
14.
Otrock ZK, Makarem JA, Shamseddine, AIVascular endothelial growth factor family of ligans and receptors: review . Blood cells Mol Dis. 2007;38:258-268.
15.
Alvarez RH, Kantarjian HM, Cortes JEBiology of platelet-derived growth factor and its involvement in disease . Mayo Clin Proc. 2006;81:1241-1257.
16.
Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AIUnderstanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood cells Mol Dis. 2007;39:212-220.
17.
Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia . N Engl J Med. 2002;346:645-652.
18.
Knapper S.FLT3 inhibition in acute myeloid leukaemia. Brit J Haematology . 2007;138:687-699.
19.
Doepfner KT , Boller D., Arcaro A.Targeting/receptor tyrosine kinase signaling in acute myeloid leukemia. Crit Rev Oncol Hematol. 2007;63:215-230.
20.
Hornick JL, Fletcher CDThe role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol. 2007;38:679-687.
Sridhar S., Hedley D., Sui LLRaf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4:677-685.
23.
Sutent [package insert]. New York, NY: Pfizer Labs; 2007.
24.
Patel PH, Chaganti RS, Motzer RJMinireview: targeted therapy for metastatic renal cell carcinoma. Brit J Cancer. 2006;94:614-619.
25.
Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
26.
Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524.
27.
Motzer RJ, Hutson TE, Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma . N Engl J Med. 2007;356:115-124.
28.
Gutierrez JC , De Oliveira LO, Perez EA, Rocha-Lima C., Livingstone AS, Koniaris LGOptimizing diagnosis, staging, and management of gastrointestinal stromal tumors. J Am Coll Surg. 2007;205:479-491.
29.
Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-1338.
30.
Eisen T., Ahmad T., Flahert KT, et al. Sorafenib in advanced melanoma: a phase II randomized discontinuation trial analysis. British J Can. 2006;95:581-586.
31.
Elser C., Siu L., Winquist E., et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinomas of the head and neck or nasopharyngeal carcinoma . J Clin Oncol. 2007;25:3766-3773.
Rosner GL, Stadler W., Ratain MJRandomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002;20:4478-4484.
34.
Ratain MJ, Eisen T., Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512.
35.
Escudier B. , Eisen T., Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;256:125-134.
36.
Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol. 2007;25:3288-3295.
37.
Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the southwest oncology group . J Clin Oncol. 2007;25:3296-3301.
38.
Llovet J., Ricci S., Mazzaferro V., et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). [Abstract]. Proc Am Soc Clin Oncol.2007;25(Suppl 18S):LBA1.
39.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A., McGuire WLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
40.
Nahta R., Francisco JEHerceptin: mechanisms of action and resistance. Cancer Lett . 2006;232:123-138.
41.
Nahta R., Yuan LX, Du Y., FJ Esteva.Lapatinib induced apoptosis in trastuzumab-resistnat breast cancer cells: effects on insulin-like growth factor 1 signaling. Mol Cancer Ther. 2007;6:667-674.
42.
Spector NL, Xia W., Burris H. 3rd, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005;23:2502-2512.
43.
Geyer CE, Martin A., Newstat MA, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: genomic and updated efficacy data. [Abstract]. Proc Am Soc. Clin Oncol.2007;25(Suppl 18S):1035.
44.
Moy B., Maltzman JD, Goss PEPhase III study of lapatinib after completion of adjuvant therapy in trastuzumabnaïve women with ErbB2-overexpressing breast cancer: Tykerb evaluation after chemotherapy (TEACH) study. The Breast.2007;16(suppl 1):S47. [P119].
45.
Piccart-Gebhart MJ, Perez EA, Baselga J., et al. P118 ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimization) study [BIG2-06/N063D/EGF106708]: a phase III study for HER2-overexpressing early breast cancer. The Breast.2007;16(suppl 1):S46-S47. [P118].
46.
Baselga J., Piccart-Gebhart MJ, Gebler RD, et al. P124 neo-ALTTO (neoadjuvant lapatinib and/or trastuzumab treatment optimization) study [BIG 1-06/SOLTI/ EGF106903]: a phase III translational study for HER2-overexpressing early breast cancer. The Breast.2007;16(suppl 1):S48. [P124].
47.
Crown JP, Burris HA, Jones S., et al. Safety and tolerability of lapatinib in combination with taxanes in patients with breast cancer. [Abstract]. Proc Am Soc Clin Oncol.2007;25(Suppl 18S):1027.
48.
Cianfrocca ME, Rose ST, von Roenn JH, et al. A phase I trial of pegylated liposomal anthracycline and lapatinib combination in the treatment of metastatic breast cancer: first evaluation of an anthracycline and lapatinib combination in the treatment of MBC. [Abstract]. Proc Am Soc Clin Oncol.2007;25(Suppl 18S):1079.
49.
Guarneri V., Frassoldati A., Cagossi K., et al. CHER-LOB: preoperative chemotherapy plus trastuzumab, lapatinib, or both in HER2-positive operable breast cancer? Preliminary safety report with focus on cardiac tolerability. In: Breast Cancer Symposium 2007. San Francisco, CA: Proceedings from the American Society of Clinical Oncology; 2007. Abstract 171.
50.
Kimball KJ, Numnum TM, Estes JM, Kirby TO, Barnes MN, Alvarez RDA phase I trial of lapatinib in combination with carboplatin in patients with platinum sensitive recurrent epithelial ovarian cancer. [Abstract]. Proc Am Soc Clin Oncol.2007;25(Suppl 18S):14106.
51.
Iqbal S., Goldman B., Lenz HJ, Fenoglio-Preiser CM, Blanke CDS0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients with advanced or metastatic gastric cancer. [Abstract]. Proc Am Soc Clin Oncol.2007;25(Suppl 18S):4621.
52.
Smylie M., Blumenschein GR, Dowlati A., et al. A phase II multicenter trial comparing two schedules of lapatinib as first or second line Monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma or no smoking history. [Abstract]. Proc Am Soc Clin Oncol.2007;25(Suppl 18S):7611.
53.
Molina JR, Erlichman C., Kaufmann S., et al. A phase I study of lapatinib and topotecan in patients with solid tumors. [Abstract]. Proc Am Soc Clin Oncol.2007;25 (Suppl 18S):3598.
54.
Tarceva [package insert]. Melville, NY: OSI Pharmaceuticals; 2007.
55.
Shepherd FA , Pereira JR, Ciuleanu T., et al. Erlotinib in previously treated Nonsmall-cell lung cancer. N Engl J Med . 2005;353:123-132.
56.
Tsao MS, Sakurada A., Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.
57.
Herbst RS, Prager D., Hermann R., et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall-cell lung cancer. J Clin Oncol. 2005;23:5892-5899.
58.
Herbst RS, Johnson DH, Mininberg E., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/Epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent nonsmall-cell lung cancer. J Clin Oncol. 2005;23 :2544-2455.
59.
McKenna S., M. Eatock.The medical management of pancreatic cancer: a review. The Oncologist. 2003;8: 149-160.
60.
Burris HA 3rd, Moore M., Anderson J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol . 1997;15:2403-2413.
61.
Moore MJ, Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients wih advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol . 2007;25:1960-1966.
62.
Talpaz M., Shah NP, Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541.
63.
Hochhaus A. , Kantarjian H., Baccarani F., et al. Dasatinib in patients with chronic phase chronic myeloid leukemia who are resistant or intolerant to imatinib: results of the CA180013 `START-C' Study. [Abstract]. Proc Am Soc Clin Oncol.2006;24(Suppl 18S):6508.
64.
Talpaz M., Apperley JF, Kim DW, et al. Dasatinib in patients with accelerated phase chronic myeloid leukemia who are resistant or intolerant to imatinib: results of the CA180005 `START-A' study. [Abstract]. Proc Am Soc Clin Oncol.2006;24(Suppl 18S):6526.
65.
Cortes JE, Kim DW, Rosti G., et al. Dasatinib in patients with chronic myelogenous leukemia in myeloid blast crisis (MBC) who are imatinib-resistant or IM-intolerant: results of the CA180006 `START-B' study. [Abstract]. Proc Am Soc Clin Oncol.2006;24(Suppl 18S):6529.
66.
Coutre S., Martinelli G., Dombret H., et al. Dasatinib in patients with chronic myelogenous leukemia in lymphoid blast crisis or Philadelphia-chromosome positive acute lymphoblastic leukemia who are imatinib-resistant or intolerant: the CA180015 `START-L' study. [Abstract]. Proc Am Soc Clin Oncol. 2006;24 (Suppl 18S): 6528.
67.
Shah NP, Rousselot P., Pasquini R., et al. Dasatinib vs high dose imatinib in patients with chronic phase chronic myeloid leukemia resistant to imatinib. Results of CA180017 START-R randomized trial. [Abstract]. Proc Am Soc Clin Oncol.2006;24(Suppl 18S):6507.
68.
Shah NP, Kim DH, Kantarjian HM, et al. Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase who are resistant or intolerant to imatinib: one year results of CA180034. [Abstract]. Proc Am Soc Clin Oncol.2007; 25(Suppl 18S):7004.
69.
Atallah EL, Kantarjian H., O'Brien S., et al. Use of dasatinib in patients with previously untreated chronic myelogenous leukemia in chronic phase. [Abstract]. Proc Am Soc Clin Oncol.2007;25(Suppl 18S):7005.
70.
Mauro MJDefining and managing imatinib resistance. Hematol . 2006;1:219-225.
71.
Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551.
72.
Kantarjian HM, Giles F., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540-3546.
Jabbour E., Cortes J., Giles F., O'Brien S., Letvak L., Kantarjian HMPreliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). [Abstract]. Blood. 2006; 108: 2172.
75.
Von Mehren M. , Reichardt P., Casali PG, et al. A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST)-Study update. [Abstract]. Proc Am Soc Clin Oncol.2007;25(Suppl 18S):10023.
76.
le Coutre P. , Gattermann N., Hochhaus A., et al. A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia in accelerated phase . [Abstract]. Proc Am Soc Clin Oncol.2007 ;25(Suppl 18S):7026.
77.
Larson R., Ottman O., Kantarjian HM, et al. A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia in blast crisis or relapsed/refractory Ph+ acute lymphoblastic leukemia. [Abstract]. Proc Am Soc Clin Oncol.2007;25(Suppl 18S):7040.
78.
Giles FJ, le Coutre P., Bhalla K., et al. A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia in chronic phase, accelerated phase or blast crisis who also failed dasatinib. [Abstract]. Proc Am Soc Clin Oncol. 2007;25(Suppl 18S):7038.
79.
Quintas-Cardama A., Kantarjian HM, Cortes J.Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007;6:834-848.
